Transformation Into Viatris Not Seen As The Solution Mylan Needs
Analysts Remain Concerned About Growth Prospects
Executive Summary
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
You may also be interested in...
Coronavirus Puts The Brakes On Mylan-Upjohn Merger
Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.
Mylan Weighs In On Coronavirus Drug Shortage Concerns
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.